Business Standard

Friday, January 17, 2025 | 06:53 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Suven starts Phase 3 trial for first home-grown Alzheimer's drug

Clinical trial randomisation is the process of assigning patients by chance to groups that receive different treatments

pharmaceutical, pharma, testing, research, doctors, health, drugs, medicine, labaratory
Premium

Top-line data from the trial is expected to be available by early 2025

Sohini Das Mumbai
Now an Indian company working on the country’s first home-grown, potentially affordable Alzheimer’s drug Masupirdine (formerly SUVN 502) is raising hopes for 6.1 million senior citizens in India suffering from dementia. Hyderabad-based Suven Life Sciences (Suven) has started recruiting patients for the Phase 3 trial of this novel drug that could possibly slow cognitive decline.

The company’s stock surged nearly 9 per cent during the day’s trade on the BSE.

Alzheimer’s is a progressive neurological, degenerative disorder that causes the brain to shrink and the brain cells to die. According to a 2021 Lancet study on the burden of neurological

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in